Brilinta is a p2y 12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome acs or a history of myocardial infarction mi. Do not start ticagrelor in patients planned to undergo urgent coronary artery bypass graft surgery cabg. Please read medication guide and full prescribing information, including boxed warnings for brilinta 60mg and 90mg tablets, at. Brilinta ticagrelor, coadministered with lowdose acetylsalicylic acid asa. Find patient medical information for ticagrelor oral on webmd including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Brilinta, a cyclopentyltriazolopyrimidine antiplatelet agent, is the first oral antagonist of the p2y12 receptor to offer reversible receptor binding. This information is intended for us consumers only bring this offer to your pharmacy with your prescription for brilinta 60mg or 90mg tablets if you are unsure about your health insurance, please talk to your pharmacist. Instruct patient to take ticagrelor exactly as directed. This emedtv article explores important safety precautions for ticagrelor, including warnings on potentially serious problems this drug may cause. It is indicated in the eu for the prevention of atherothrombotic events in adults with acute coronary syndromes acs unstable angina pectoris, stsegment elevation myocardial infarction stemi or nonstemi. Brilinta tablets fda prescribing information, side.
Eligible commercially insured patients with a valid prescription for brilinta ticagrelor. With the brilinta savings card, eligible patients can pay less for brilinta ticagrelor tablets, save each time they refill, and maintain the benefit for the entire prescription duration. Formulation development and evaluation of ticagrelor. Discontinue ticagrelor 5 days before planned surgical procedures. Pdf ticagrelor is frequently discontinued in a real. Brilinta is the brand name of the generic prescription drug ticagrelor. This supplemental new drug application provides for revisions to the labeling as follows. When possible, interrupt therapy with brilinta for fivedays prior to. Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding. Pdf safety of ticagrelor compared with aspirin alone in. Impact of ticagrelor reload on pharmacodynamic profiles. Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses 12, 24, 36, 48, 60, 72, and 84 h. Ticagrelor is a uvabsorbing molecule with specific chromophores in the structure that absorb at a particular wavelength and this fact was successfully employed for their quantitative determinations using the uv spectrophotometric method.
Ticagrelor is a drug administered to maintain the thickness of the blood by preventing the platelets in the blood from sticking together and forming a clot. Ticagrelor keeps the platelets in your blood from coagulating clotting to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions. Ticagrelor is available in 90 mg tablets under the commercial name brilinta. Prescription hope is a nationally recognized prescription medication access program, headquartered in columbus, ohio. Ticagrelor should not be used in patients with active pathological bleeding or a history of intracranial hemorrhage. Clinicians should not prescribe ticagrelor for patients who are expected to undergo urgent cabg surgery. Premature discontinuation of therapy may increase risk of myocardial infarction, stent thrombosis, and death. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment.
Ticagrelor was approved for use in the united states in 2011 and has been used in limited numbers of patients for a limited time only. Shortness of breath, headaches, nosebleeds, chest pain, depression, bruising, blood blisters inside mouth. Ticagrelor brilinta, an antiplatelet drug for acute. Department of health and human services silver spring md 20993. Vision impaired people having problems accessing certain pages of a pdf. Ticagrelor interactions bnf content published by nice. Brilinta contains ticagrelor, a cyclopentyltriazolopyrimidine, which inhibits platelet activation and aggregation mediated by the p2y 12 adp receptor. Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10. Capitals indicate lifethreatening, underlines indicate most frequent. Ticagrelor pronounced tie ka grel or other names for this medicine. Ticagrelor brilinta is a new oral antiplatelet medicine, which has been available, fully subsidised, with special authority, since 1 july, 20. In the case of intolerable dyspnea requiring discontinuation of brilinta, consider prescribing another antiplatelet agent.
Brilinta is used to lower your chance of having a heart attack or dying from a heart attack or stroke but brilinta and similar drugs can cause bleeding that can be serious and sometimes lead to death. Ticagrelor was prescribed after acs or stemi to and 174 patients, respectively. Brilinta ticagrelor side effects, dosage, interactions. Ticagrelor is a substrate of cyp3a45 and pglycoprotein pgp, and ritonavir is a potent cyp3a4 inhibitor and a pgp inhibitor.
Ticagrelor fails to improve on clopidogrel after switch singlecenter study contradicts plato in acs patients. Both ticagrelor and parecoxib can increase the risk of bleeding. Are you looking for a place to get your brilinta ticagrelor at an affordable cost. Ticagrelor trade name brilinta, brilique, and possia is a platelet aggregation inhibitor produced by astrazeneca. According to the plato trial, ticagrelor is associated with ventricular pauses in the first week of treatment. See what others have said about brilinta ticagrelor, including the effectiveness, ease of use and side effects. We present a case of ticagrelor related seconddegree type ii. Ticagrelor, coadministered with low dose aspirin, is an alternative to clopidogrel for the prevention of atherothrombotic events in patients with acute coronary syndromes. Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 mcgml at room.
Brilinta 90 mg tablets for oral administration contain 90 mg of ticagrelor and the following ingredients. The chemical structure of ticagrelor is shown in figure 1. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to brilinta, no specific treatment is required. Figure 2 major fatallifethreatening cabgrelated bleeding by days from last dose of study drug to cabg procedure plato. Ticagrelor information for patients read this medicine fact sheet to learn about. Stopping ticagrelor abruptly can cause an increased risk for myocardial infarction, stent thrombosis, and death breastfeeding. Under warnings and precautions, the following section was added. Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage. Ticagrelor fails to improve on clopidogrel after switch. Ticagrelor should not be given to people who are likely to need heart bypass surgery. Ticagrelor prevents platelets in your blood from sticking together to form an unwanted blood clot that could block an artery. A total of 60 patients will be randomized into one of the following two arms of treatment. Cangrelor ticagrelor transition study full text view. Ticagrelor is frequently discontinued in a real world setting.
Ticagrelor definition of ticagrelor by medical dictionary. This prior approval supplemental new drug application provides for labeling changes to describe a new. Medication guide brilinta brihlintah ticagrelor tablets read this medication guide before you start taking brilinta and each time you get a refill. Stsegmentelevation myocardial infarction stemi current australian guidelines recommend treatment with aspirin and clopidogrel for up to 12 months after an stsegment. Its used, along with low doses of aspirin, to reduce the risk of a serious heart problem or stroke in people whove already. Ticagrelor is used together with aspirin to lower your risk of having a stroke or serious heart problems after youve had a heart attack or severe chest pain ticagrelor may also be used for purposes not listed in this medication guide. In an international study it was found to be more effective. What is the most important information i should know about brilinta. Ticagrelor is an antagonist of the p2y 12 receptor.
Ticagrelor warnings and precautions heart home page. Had 3 stents implanted 20 years ago and was prescribed plavix for 30 days. Ticagrelor is used to lower your risk of having a stroke or serious heart problems after you have had a. Concomitant use is expected to increase ticagrelor exposure, which may increase bleeding risk. Ticagrelor is a platelet aggregation inhibitor which was and drug administration on july 20, 2011 fda, 2011. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. Ticagrelor was found to be excreted in the breast milk of lactating rats, but the excretion of ticagrelor in human breast milk. Ticagrelor, like other antiplatelet drugs, can cause significant, sometimes fatal, bleeding. We acknowledge receipt of your amendment dated january 24, 20 and your risk evaluation and mitigation strategy rems assessment dated august 14, 2012. Current indications are reduction of recurrent cardiovascular events in patients with acute coronary syndromes. Persons with disabilities having problems accessing the pdf files below may call 301 7963634 for assistance.
What this medicine is why you need to take it what side effects to watch for what is the name of my medicine. For at least the first 12 months following acs, it is superior to clopidogrel. No problem with plavix and no heart related issues for 20 years until this. Ticagrelor in combination with aspirin is an alternative to clopidogrel and aspirin or prasugrel and aspirin in people with an acute coronary syndrome mi or unstable angina. Ticagrelor is indicated for the prevention of thrombotic events for example stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with st elevation. Brilinta ticagrelor dosing, indications, interactions.
Hypersensitivity to ticagrelor or any component of the product 4. Results of the plato substudy of acs patients undergoing an invasive strategy have been published in the lancet, accompanied by a comment from gregg stone hailing the introduction of ticagrelor as a landmark event that will redefine the care of acs patients. When possible, interrupt therapy with brilinta for fivedays prior to surgery that has a major risk of bleeding. The scope of the present study is to evaluate the impact of ticagrelor reload in patients on chronic ticagrelor therapy.
Ticagrelor is a triazolopyrimidine that is an adenosine isostere. Savings card eligibility brilinta ticagrelor tablets. Brilinta ticagrelor dose, indications, adverse effects. Eligibility for free trial offer for medicare or medicaid patients. Omega3acid ethyl esters is predicted to increase the risk of bleeding events when given with ticagrelor. If ticagrelor must be temporarily discontinued, restart as soon as possible.
The drug was approved for use in the european union by the european medicines agency on december 3, 2010. This information does not take the place of talking with your doctor about your medical condition or your treatment. Brilinta, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. Patients with acute coronary syndromes acs patients with a history of myocardial infarction mi occurred at least one year ago and.
1620 1192 1411 317 1128 152 1091 207 1043 191 1317 1099 328 690 928 1480 150 445 1005 971 84 724 76 1138 994 613 563 540 618 879 119 186 755 598 1111 1370 1370 740 902 1391